SCHEMBL25184331

SCHEMBL25184331

CC(C)(C)OC(=O)Nc1c(-c2cc(F)ccc2F)ccnc1C1CCC(F)(F)CC1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 4/20 0.38
CCNT1 O60563 3/20 0.38
GSK3B P49841 3/20 0.36
GSK3A P49840 1/20 0.36
IDO1 P14902 1/20 0.36
MAPT P10636 2/20 0.36
ATR Q13535 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.35
BDKRB1 P46663 2/20 0.35
RORC P51449 2/20 0.35
ABL1 P00519 2/20 0.34
AAK1 Q2M2I8 2/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26151941 0.89 GSK3B (0.38) GSK3BGSK3AIDO1MAPTATR
SCHEMBL30418690 0.89 CDK9 (0.38) CDK9CCNT1GSK3BGSK3AIDO1
SCHEMBL30445285 0.89 GSK3B (0.38) GSK3BGSK3AIDO1MAPTATR
SCHEMBL26152085 0.89 CDK9 (0.38) CDK9CCNT1GSK3BGSK3AIDO1
SCHEMBL31058902 0.89 CDK9 (0.38) CDK9CCNT1GSK3BGSK3AIDO1
SCHEMBL31058907 0.88 CDK9 (0.36) CDK9CCNT1ATRSCN10ARORC
SCHEMBL26152168 0.88 CDK9 (0.36) CDK9CCNT1ATRSCN10ARORC
SCHEMBL30417617 0.88 CDK9 (0.36) CDK9CCNT1ATRSCN10ARORC
SCHEMBL25180704 0.88 GSK3B (0.38) GSK3BGSK3AIDO1MAPTSCN10A
SCHEMBL30444878 0.87 GSK3B (0.36) CDK9CCNT1GSK3BGSK3AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-04-24 US disclosed
EP-4405344-A2 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS Xenon Pharmaceuticals Inc. (CA) 2024-07-31 EP disclosed
CN-118251389-A Pyridyl derivatives as sodium channel activators 泽农医药公司 2024-06-25 CN disclosed
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-05-18 US disclosed
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-05-18 US disclosed
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-05-18 US disclosed
WO-2023049369-A2 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B CDK9 2783/4885CCNT1 2930/4885GSK3B 249/4885
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B CDK9 2783/4885CCNT1 2930/4885GSK3B 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.